Screener
Praxis Precision Medicines, Inc. PRAX Business Segments — Total stock-based compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001689548-26-000083
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Elsunersen | 8,141 | 1,317 | 11,338 | 2,078 |
| Other early stage assets | 5,471 | 1,417 | 8,713 | 2,522 |
| Personnel-related expenses | 18,943 | 11,913 | 36,673 | 24,943 |
| Stock-based compensation expense | 11,309 | 7,770 | 28,421 | 16,556 |
| Depreciation expense | 33 | 46 | 72 | 93 |
| Other segment expenses(a) | 12,851 | 6,753 | 24,940 | 15,129 |
| Other income, net | 13,184 | 4,940 | 26,483 | 10,372 |
| Consolidated net loss | $(83,720) | $(71,127) | $(176,281) | $(140,423) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Praxis Precision Medicines, Inc.'s business segments — total stock-based compensation expense?
- Praxis Precision Medicines, Inc. (PRAX) reported business segments — total stock-based compensation expense of $11.31M in Q2 2026.
- How has Praxis Precision Medicines, Inc.'s business segments — total stock-based compensation expense changed year-over-year?
- Praxis Precision Medicines, Inc.'s business segments — total stock-based compensation expense increased by 45.5% year-over-year, from $7.77M to $11.31M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s business segments — total stock-based compensation expense?
- Over 2 years (2023 to 2025), Praxis Precision Medicines, Inc.'s business segments — total stock-based compensation expense has grown at a 16.9% compound annual growth rate (CAGR), from $24.86M to $33.94M.
- What does business segments — total stock-based compensation expense mean?
- This metric measures the non-cash expense recognized for equity-based awards granted to employees and directors within the business segment. It is a critical component of talent retention and incentive alignment in the biopharmaceutical industry. Investors track this to understand the dilution impact and the true cost of labor beyond cash compensation.
Ask your AI about Praxis Precision Medicines, Inc.'s business segments — total stock-based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude